Skip to main content

Merck (MRK) and Pfizer (PFE) Initiate Two Phase III Studies of Avelumab in Advanced GEJ Cancers

Merck KGaA (NYSE: MRK), Darmstadt, Germany, and Pfizer (NYSE: PFE) today announced the initiation of two Phase III studies of avelumab*, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody, in treating advanced or metastatic gastric/gastro-esophageal junction (GEJ) cancers, which are aggressive cancers with poor survival rates. These pivotal trials are investigating avelumab in the first-line and third-line settings, with overall survival (OS) as the primary endpoint in both trials.
http://www.streetinsider.com/Corporate+News/Merck+(MRK)+and+Pfizer+(PFE)+Initiate+Two+Phase+III+Studies+of+Avelumab+in+Advanced+GEJ+Cancers/11139944.html

No Comments yet!

Your Email address will not be published.

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2022 Esophageal Cancer Education Foundation- by domino